Improved Trimethylangelicin Analogs for Cystic Fibrosis: Design, Synthesis and Preliminary Screening

A small library of new angelicin derivatives was designed and synthesized with the aim of bypassing the side effects of trimethylangelicin (TMA), a promising agent for the treatment of cystic fibrosis. To prevent photoreactions with DNA, hindered substituents were inserted at the 4 and/or 6 positions. Unlike the parent TMA, none of the new derivatives exhibited significant cytotoxicity or mutagenic effects. Among the synthesized compounds, the 4-phenylderivative 12 and the 6-phenylderivative 25 exerted a promising F508del CFTR rescue ability. On these compounds, preliminary in vivo pharmacokinetic (PK) studies were carried out, evidencing a favorable PK profile per se or after incorporation into lipid formulations. Therefore, the selected compounds are good candidates for future extensive investigation to evaluate and develop novel CFTR correctors based on the angelicin structure.

[1]  E. Franceschinis,et al.  Self-Emulsifying Formulations to Increase the Oral Bioavailability of 4,6,4′-Trimethylangelicin as a Possible Treatment for Cystic Fibrosis , 2022, Pharmaceutics.

[2]  J. Davies,et al.  An Update on CFTR Modulators as New Therapies for Cystic Fibrosis , 2022, Pediatric Drugs.

[3]  Xin He,et al.  Self-Nanoemulsifying Drug Delivery System of Genkwanin: A Novel Approach for Anti-Colitis-Associated Colorectal Cancer , 2021, Drug design, development and therapy.

[4]  M. Conese,et al.  The preclinical discovery and development of the combination of ivacaftor + tezacaftor used to treat cystic fibrosis , 2020, Expert opinion on drug discovery.

[5]  Sheridan M. Hoy.  Elexacaftor/Ivacaftor/Tezacaftor: First Approval , 2019, Drugs.

[6]  O. Cuesta-Rubio,et al.  Nemorosone inhibits the proliferation and migration of hepatocellular carcinoma cells. , 2019, Life sciences.

[7]  René Holm,et al.  Bridging the gaps between academic research and industrial product developments of lipid-based formulations. , 2019, Advanced drug delivery reviews.

[8]  G. Lippi,et al.  Molecular Mechanism of Action of Trimethylangelicin Derivatives as CFTR Modulators , 2018, Front. Pharmacol..

[9]  C. Bear,et al.  Correctors of the Major Cystic Fibrosis Mutant Interact through Membrane-Spanning Domains , 2018, Molecular Pharmacology.

[10]  R. Gambari,et al.  Design, synthesis and biological evaluation of novel trimethylangelicin analogues targeting nuclear factor kB (NF-kB). , 2018, European journal of medicinal chemistry.

[11]  C. Bear,et al.  The investigational Cystic Fibrosis drug Trimethylangelicin directly modulates CFTR by stabilizing the first membrane-spanning domain. , 2016, Biochemical pharmacology.

[12]  E. Deeks.  Lumacaftor/Ivacaftor: A Review in Cystic Fibrosis , 2016, Drugs.

[13]  Garry R. Cutting,et al.  Cystic fibrosis genetics: from molecular understanding to clinical application , 2014, Nature Reviews Genetics.

[14]  R. Gambari,et al.  Trimethylangelicin promotes the functional rescue of mutant F508del CFTR protein in cystic fibrosis airway cells. , 2014, American journal of physiology. Lung cellular and molecular physiology.

[15]  R. Gambari,et al.  Trimethylangelicin reduces IL-8 transcription and potentiates CFTR function. , 2011, American journal of physiology. Lung cellular and molecular physiology.

[16]  N. Pedemonte,et al.  High-throughput screening of libraries of compounds to identify CFTR modulators. , 2011, Methods in molecular biology.

[17]  B. Cosimelli,et al.  A convenient synthesis of psoralens , 2002 .

[18]  E. Zeiger,et al.  The Ames Salmonella/microsome mutagenicity assay. , 2000, Mutation research.

[19]  E. Sage,et al.  MONOFUNCTIONAL ANGULAR FUROCOUMARINS: SEQUENCE SPECIFICITY IN DNA HOTOBINDING OF 6,4,4′‐TRIMETHYLANGELICIN and OTHER ANGELICINS , 1989, Photochemistry and photobiology.

[20]  F. Dall'acqua,et al.  6-Methylangelicins: a new series of potential photochemotherapeutic agents for the treatment of psoriasis. , 1984, Journal of medicinal chemistry.

[21]  B. Ames,et al.  Revised methods for the Salmonella mutagenicity test. , 1983, Mutation research.

[22]  J. Gustafson,et al.  Cystic Fibrosis , 2009, Journal of the Iowa Medical Society.